All Wales Medicines Strategy Group (AWMSG)
Record ID 32014001439
Authors' recomendations: Velaglucerase alfa (VPRIV®) is recommended as an option for use within NHS Wales for long-term enzyme replacement therapy in patients with type 1 Gaucher disease. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Project Status: Completed
Year Published: 2014
URL for published report: http://www.awmsg.org/awmsgonline/app/appraisalinfo/571
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Wales, United Kingdom
- Gaucher Disease
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name: AWTTC@wales.nhs.uk
Contact Email: AWTTC@wales.nhs.uk
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.